109 related articles for article (PubMed ID: 16178897)
1. Expression of CD 44 s, CD 44 v 3 and CD 44 v 6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan.
Auvinen P; Tammi R; Tammi M; Johansson R; Kosma VM
Histopathology; 2005 Oct; 47(4):420-8. PubMed ID: 16178897
[TBL] [Abstract][Full Text] [Related]
2. Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation.
Karihtala P; Soini Y; Auvinen P; Tammi R; Tammi M; Kosma VM
J Histochem Cytochem; 2007 Dec; 55(12):1191-8. PubMed ID: 17827165
[TBL] [Abstract][Full Text] [Related]
3. Expression of hyaluronan in benign and malignant breast lesions.
Auvinen PK; Parkkinen JJ; Johansson RT; Agren UM; Tammi RH; Eskelinen MJ; Kosma VM
Int J Cancer; 1997 Oct; 74(5):477-81. PubMed ID: 9355968
[TBL] [Abstract][Full Text] [Related]
4. CD24 expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Bircan S; Kapucuoglu N; Baspinar S; Inan G; Candir O
Pathol Res Pract; 2006; 202(8):569-76. PubMed ID: 16828238
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD44s, CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast.
Afify A; McNiel MA; Braggin J; Bailey H; Paulino AF
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):121-7. PubMed ID: 18227732
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression.
Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR
Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308
[TBL] [Abstract][Full Text] [Related]
7. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
8. Reduced expression of Claudin-7 in fine needle aspirates from breast carcinomas correlate with grading and metastatic disease.
Sauer T; Pedersen MK; Ebeltoft K; Naess O
Cytopathology; 2005 Aug; 16(4):193-8. PubMed ID: 16048505
[TBL] [Abstract][Full Text] [Related]
9. Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study.
Xie F; Wang Q; Chen Y; Gu Y; Mao H; Zeng W; Zhang X
Pathol Res Pract; 2010 Nov; 206(11):735-9. PubMed ID: 20634005
[TBL] [Abstract][Full Text] [Related]
10. A comparison of the patterns of laminin expression in fibroadenoma, fibrocystic diseases, pre-invasive and invasive ductal breast carcinoma.
Zheng WQ; Looi LM; Cheah PL
Pathology; 2001 Aug; 33(3):303-6. PubMed ID: 11523929
[TBL] [Abstract][Full Text] [Related]
11. The expression of FHIT, PCNA and EGFR in benign and malignant breast lesions.
Terry G; Ho L; Londesborough P; Duggan C; Hanby A; Cuzick J
Br J Cancer; 2007 Jan; 96(1):110-7. PubMed ID: 17164758
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis.
Shen D; Nooraie F; Elshimali Y; Lonsberry V; He J; Bose S; Chia D; Seligson D; Chang HR; Goodglick L
Hum Pathol; 2006 Dec; 37(12):1583-91. PubMed ID: 16949910
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of E-cadherin in lobular and ductal neoplasms of the breast and its biologic and diagnostic implications.
Acs G; Lawton TJ; Rebbeck TR; LiVolsi VA; Zhang PJ
Am J Clin Pathol; 2001 Jan; 115(1):85-98. PubMed ID: 11190811
[TBL] [Abstract][Full Text] [Related]
14. Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer.
Chang H; Mohabir N; Done S; Hamel PA
J Clin Pathol; 2009 Oct; 62(10):908-14. PubMed ID: 19783719
[TBL] [Abstract][Full Text] [Related]
15. Increased hyaluronan content and stromal cell CD44 associate with HER2 positivity and poor prognosis in human breast cancer.
Auvinen P; Tammi R; Kosma VM; Sironen R; Soini Y; Mannermaa A; Tumelius R; Uljas E; Tammi M
Int J Cancer; 2013 Feb; 132(3):531-9. PubMed ID: 22753277
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
17. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
18. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
19. Fibronectin expression in carcinoma cells correlates with tumor aggressiveness and poor clinical outcome in patients with invasive breast cancer.
Bae YK; Kim A; Kim MK; Choi JE; Kang SH; Lee SJ
Hum Pathol; 2013 Oct; 44(10):2028-37. PubMed ID: 23684510
[TBL] [Abstract][Full Text] [Related]
20. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
